Prevent osteoporosis by understanding low bone density, risk factors, prevention strategies, and treatment options for ...

The UK osteoporosis fracture healing market is on a steady growth trajectory, with market size expected to reach USD 738.6 million by 2025. Driven by an increasing prevalence of osteoporosis-related ...

Researchers have found in a new study that a high cardiovascular health score is associated with lower odds of osteoporotic ...

Multivitamin and cocoa extract supplements do not protect against clinical fractures for older adults, according to data ...

The Conservatives say if they were in power they would be rolling out the life-saving fracture services Labour said they ...

The FDA has approved Stoboclo (denosumab-bmwo), a biosimilar to Prolia (denosumab), and Osenvelt (denosumab-bmwo), a biosimilar to Xgeva (denosumab).

A new study published in the journal of BMC Gasteroenterology found that patients with the liver cirrhosis had higher risk of ...

In accordance with a settlement agreement with Amgen Inc., STOBOCLO and OSENVELT are expected to be available in the U.S. in June 2025.

Patients with mCRPC prostate cancer have an elevated risk of fractures due to bone metastases and use of androgen receptor pathway inhibitors (ARPI).

Stoboclo, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Osenvelt, a ...

The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for ...

US FDA approves Celltrion’s Stoboclo and Osenvelt biosimilars referencing Prolia and Xgeva: Jersey City, New Jersey Wednesday, March 5, 2025, 18:00 Hrs [IST] Celltrion, a leadin ...